American Society of Hematology

Special-Interest Sessions

These smaller sessions provide the opportunity for ASH’s various communities to focus on specific topics of interest, ranging from how to incorporate palliative care into practice, to how to garner support and resources for systems-based hematology, to the reach of ASH’s international outreach programs.

Special-Interest Session at the ASH Annual Meeting

ASH Choosing Wisely® Campaign: 2018 ASH Choosing Wisely Champions

Monday, December 3, 2018, 12:15 p.m. - 1:15 p.m.
San Diego Convention Center, Room 30D

In cooperation with the ABIM Foundation, ASH has introduced the Choosing Wisely Champions initiative to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures. Each year, three individuals are invited to present on successful utilization strategies that they have developed and implemented in their practice, institution, or hospital system. This provides an opportunity for clinicians, administrators, and other medical professionals to learn about projects that might be translated to their own practices.

Chair:

Anita Rajasekhar, MD
University of Florida Health Shands Hospital
Gainesville, FL

Speakers:

Adam F. Binder, MD
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
Philadelphia, PA
Reduction in Inappropriate Vancomycin Prescribing for Febrile Neutropenia

Ming Yeong Lim, MBBChir
Medical University of South Carolina
Mount Pleasant, SC
Reduction in Use of Direct Thrombin Inhibitors (DTIs) in Patients With Suspected HIT

Prakash Vishnu, MD
Mayo Clinic Florida
Jacksonville, FL
Reduction in Unnecessary Red Blood Cell Transfusion in HSCT Patients

back to top

ASH Foundation Run/Walk

Sunday, December 2, 2018, 7:00 a.m. - 9:00 a.m.
San Diego Convention Center, Embarcadero Marina Park South

back to top

ASH Practice Partnership Lunch

How to Incorporate Palliative Care Into Practice: Addressing Barriers and Solutions

Sunday, December 2, 2018, 11:15 a.m. - 12:30 p.m.
Marriott Marquis San Diego Marina, Marina Ballroom G

Patients with hematologic malignancies often have difficulty accessing high-quality symptom management and palliative care because of preconceived perceptions as well as limited reimbursement. The benefits of palliative care for patients, families, and the health care system include improved quality of life, better symptom management, improved coping, better prognostic awareness, enhanced ability to meet patient preferences for place of death, reduced costs, fewer hospital readmissions, and even improved survival.

To help attendees understand how to better incorporate palliative care into hematology practice, the speakers will address relevant barriers and potential solutions. Specifically, they will address issues related to physician and patient perception, limited reimbursement, and educational opportunities to help overcome barriers to palliative care.

For more on the topic of palliative care, please see the Special Symposium on Quality session, which will focus on how the quality of symptom management, palliative care, and EOL care should be measured for patients with blood cancers, as many of the existing metrics seem to have limited relevance. 

The ASH Practice Partnership is the Society's network of practice-based hematologists with interests in practice-related policies, quality of care, new health care delivery systems, and practice management issues. The ASH Practice Partnership Lunch is a special session designed for this community.

Chair:

Joseph C. Alvarnas, MD
City of Hope National Medical Center
Duarte, CA

Speakers:

Areej El-Jawahri, MD
Massachusetts General Hospital
Boston, MA
Changing the Perception of Palliative Care for Physicians and Patients

Tammy Kang, MD
Texas Children's Hospital
Houston, TX
Barriers and Solutions to Integrating Palliative Care Into Hematology

Robert Arnold
University of Pittsburgh
Pittsburgh, PA
Palliative Care Communication at the End of Life

back to top

ASH-FDA Joint Symposium on New Drug Approvals I

Monday, December 3, 2018, 10:30 a.m. - 12:00 p.m.
San Diego Convention Center, Hall AB

This joint session, one of two co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat hematological disorders. FDA product-reviewers will discuss the safety and efficacy issues for the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time for questions from the audience. back to top

ASH-FDA Joint Symposium on New Drug Approvals II

Monday, December 3, 2018, 4:30 p.m. - 6:00 p.m.
San Diego Convention Center, Hall AB

This joint session, one of two co-sponsored by the U.S. Food and Drug Administration (FDA), will feature drugs recently approved to treat hematological disorders. FDA product-reviewers will discuss the safety and efficacy issues for the products' clinical trials and toxicity studies. The program will also include clinicians who will discuss their perspectives on the use of the products in the real-world setting. There will be ample time for questions from the audience. back to top

Blood and Beyond: Cancer- what it does to you AND for you

Sunday, December 2, 2018, 4:30 p.m. - 6:00 p.m.
San Diego Convention Center, Room 6F

Scientifically and clinically, the study of blood commands a professional engagement that can lead hematologists to lose sight of the complex notions held by the non-medical world. The editors of the Blood journal take this opportunity to highlight the intersection of hematology and humanities by bringing to light the epic story of blood, the care of patients, and the role that Blood has played in the advancement of the new hematologic discoveries.

Chair:

Bob Löwenberg, MD, PhD
Editor-in-Chief, Blood, Erasmus University Medical Center
Rotterdam, Netherlands

Speakers:

Kenneth C. Anderson, MD
Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School
Boston, MA
Introduction of Speaker

Tom Brokaw
Special Correspondent, NBC News
New York City, NY
Cancer- what it does to you AND for you

back to top

Consultative Hematology Course

Monday, December 3, 2018, 7:00 a.m. - 11:30 a.m.
Marriott Marquis San Diego Marina, Marina Ballroom DE

This interactive course, intended for clinical hematologist based in community practice in North America, will cover commonly encountered clinical problems that require the expertise of a hematologist. Faculty familiar with consultative practice issues will focus on non-malignant hematology topics, such as thrombosis, iron replacement therapy, and sickle cell disease. For more information, visit https://www.hematology.org/CHC/Program/.

If you are interested in registering for this course but are not planning to register for the annual meeting, please contact ashregistration@spargoinc.com. Advance online registration is limited to clinical hematologists practicing in North America; on-site registration will be possible for other groups if space is available.

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

ASH designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Co-Chairs:

Donald M. Arnold, MD, MSc, FRCPC
McMaster University
Hamilton, ON, Canada

Maureen Achebe, MD
Brigham and Women's Hospital
Boston, MA

back to top

Featured Topic: Novel Therapies and Taxonomy in Lymphoid Neoplasms: Are We Ready for the Shift?

Sunday, December 2, 2018, 11:15 a.m. - 12:15 p.m.
San Diego Convention Center, Room 7B

This session will highlight research that was submitted as abstracts and presented predominantly as posters at the annual meeting. In this session, a pair of experts will summarize the abstracts and comment on their relevance to an emerging and timely research area. back to top

Featured Topic: Sickle Cell Disease: New Drugs, Curative Approaches

Monday, December 3, 2018, 12:15 p.m. - 1:15 p.m.
San Diego Convention Center, Room 28D

This session will highlight research that was submitted as abstracts and presented predominantly as posters at the annual meeting. In this session, a pair of experts will summarize the abstracts and comment on their relevance to an emerging and timely research area. back to top

Global Hematology Symposium

Monday, December 3, 2018, 12:15 p.m. - 1:15 p.m.
San Diego Convention Center, Room 6E

This session will focus on the application of gene editing to control mosquito populations in Africa’s malaria belt. The technique, referred to as a “gene drive,” uses CRISPR technology to modify the genes of mosquitoes to drastically reduce the number of malaria-transmitting organisms in countries where the disease is known to have a devastating impact. The Bill and Melinda Gates Foundation has prioritized malaria and has dedicated vast funds in hopes of introducing these interventions in the near future. However, there are concerns that limited transparency around the current research may undermine public support and, therefore, hinder implementation and potential benefits of the program.

Dr. Andrea Crisanti will provide an overview of the science and potential efficacy of these interventions.

Dr. Kevin Esvelt will elaborate on challenges associated with the current research model and how this may affect implementation.

The session will include a 10-minute question and answer portion and will be moderated by Dr. Leslie Kean.

Chair:

Leslie Kean, MD, PhD
Boston Children's Hospital
Boston, MA

Speakers:

Andrea Crisanti, PhD
Imperial College London
London, United Kingdom
Overview and Potential Efficacy of Gene Drive Interventions

Kevin M. Esvelt, PhD
Massachusetts Institute of Technology
Cambridge, MA
Challenges With Implementation of Gene Drive Interventions

back to top

Grassroots Network Lunch

Saturday, December 1, 2018, 11:15 a.m. - 12:15 p.m.
Marriott Marquis San Diego Marina, Marina Ballroom G

Thanks to ASH’s advocacy efforts and the ASH Grassroots Network, issues important to the future of hematology have been brought to the attention of the U.S. Congress and federal agencies. The ASH Grassroots Lunch provides a forum for interested members to learn how they can participate in ASH’s advocacy efforts, communicate with Congress, become effective advocates for hematology, and discuss the Society’s legislative and regulatory priorities.

Dr. Jason Westin, an ASH member who ran for a seat in the U.S. House of Representatives from Texas' 7th Congressional District, will be the featured speaker at this year's lunch.  Dr. Westin will discuss his experience as a candidate for elected office and share his thoughts on the importance of physicians and scientists being involved in advocacy and the political process.

Moderator:

Alan G Rosmarin, MD
Wolters Kluwer Health
Waltham, MA

back to top

Hematology Course Directors' Workshop

Sunday, December 2, 2018, 7:00 a.m. - 9:00 a.m.
Hilton San Diego Bayfront, Cobalt 500

This workshop is intended to provide course directors and others involved in teaching hematology to medical students with opportunities to learn about issues facing them. It is designed to facilitate discussion and the sharing of best practices in critical training areas.

Chair:

Rakesh P. Mehta, MD
Indiana University School of Medicine
Indianapolis, IN

Speaker:

Timothy James J. Littlewood, MD
University of Oxford
Oxford, United Kingdom
Teaching Hematology: Art, Science, and Humanity

back to top

How to Get Published in a Peer-Reviewed Journal

Saturday, December 1, 2018, 11:15 a.m. - 12:15 p.m.
San Diego Convention Center, Room 7B

The ability to communicate one’s work effectively by publication in high-impact journals is a benchmark for success in academic medicine. Even high-quality work may not be accepted if not presented in a well-crafted manuscript. This talk will provide insight into the elements of a high-quality manuscript worthy of publication in Blood and tips on avoiding common errors that might result rejection.

Chair:

Bob Löwenberg, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

back to top

MDS + AML MATTER: A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection

Saturday, December 1, 2018, 9:30 a.m. - 11:00 a.m.
San Diego Convention Center, Ballroom 20D

This session will be conducted in the style of a tumor board. The panelists will focus on the evaluation of the patient, prognosis, treatment, and management of complications of therapy. Risk stratification and role of mutational analysis and MRD will be addressed and there will be discussion about treatment in the setting of newly approved therapies including the role of stem cell transplant.
Extensive audience participation will be encouraged.

MDS+AML MATTER is an education program designed to improve the diagnosis and treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The program is hosted by the American Society of Hematology (ASH), American Society for Clinical Pathology (ASCP), National Marrow Donor Program (NMDP), Oncology Nursing Society (ONS), and The France Foundation. ASH thanks Celgene for their support of the program.

The goals of the program are to provide guidance to the interdisciplinary MDS/AML care team on:

  • The optimal diagnosis and classification of both MDS and AML
  • Risk stratification and individualized treatment selection
  • Assessment of treatment responses
  • Monitoring for and mitigation of adverse events, and
  • Patient education regarding prognosis and treatment choices

Chair:

Jessica K. Altman, MD
Northwestern University
Chicago, IL

Speakers:

Jessica K. Altman, MD
Northwestern University
Chicago, IL
Tumor Board Panelist

Linda J. Burns, MD
National Marrow Donor Program/Be the Match
Minneapolis, MN
Tumor Board Panelist

B. Douglas Smith, MD
Johns Hopkins University School of Medicine
Baltimore, MD
Tumor Board Panelist

Michael A. Linden, MD,PhD
University of Minnesota
Minneapolis, MN
Tumor Board Panelist

back to top

Meet the Blood Editors

Sunday, December 2, 2018, 11:15 a.m. - 12:15 p.m.
Hilton San Diego Bayfront, Cobalt 520

These sessions provide the opportunity for attendees to meet with the associate editors of Blood and discuss recent changes to the journal as well as submission and peer-review processes and policies, with each session giving a unique focus. Seating is limited and available on a first-come, first-served basis.

Panelists:

Nancy Berliner, MD
Brigham and Women's Hospital
Boston, MA
Meet the Blood Editors

Margaret Goodell, PhD
Baylor College of Medicine
Houston, TX
Meet the Blood Editors

back to top

Meet the Blood Editors

Monday, December 3, 2018, 12:15 p.m. - 1:15 p.m.
Hilton San Diego Bayfront, Cobalt 520

These sessions provide the opportunity for attendees to meet with the associate editors of Blood and discuss recent changes to the journal as well as submission and peer-review processes and policies, with each session giving a unique focus. Seating is limited and available on a first-come, first-served basis.

Panelists:

Catherine M. Bollard, MD
Children's National Medical Center
Washington, DC
Meet the Blood Editors

Freda K Stevenson, PhD
University of Southampton
Southampton, United Kingdom
Meet the Blood Editors

back to top

Networking Reception for Female Hematologists

Monday, December 3, 2018, 7:30 p.m. - 9:30 p.m.
Manchester Grand Hyatt San Diego, Coronado Ballroom

This workshop and networking reception will provide an opportunity for female hematologists to gather in an informal environment. The goal of the event is to facilitate an exchange between senior and more junior hematologists in an effort to cultivate mentoring. In addition to remarks from the co-chairs, this year the event will feature a keynote speaker on leadership.

Speakers:

Margaret Cary, MD, MBA, MPH, PCC
The Cary Group
Washington, DC
Networking Reception for Female Hematologists

Amy E. DeZern, MD
Johns Hopkins University
Baltimore, MD
Networking Reception for Female Hematologists

Jyoti Nangalia, MBBChir, PhD
Wellcome Trust Sanger Institute
Hinxton, United Kingdom
Networking Reception for Female Hematologists

back to top

Promoting Minorities in Hematology Presentations and Reception

Saturday, December 1, 2018, 6:30 p.m. - 9:30 p.m.
Marriott Marquis San Diego Marina, Marina Ballroom EFG

ASH invites all interested meeting attendees to this event, which will showcase training and research opportunities geared toward increasing the diversity of scholars in the field of hematology. The highlight of the session will be scientific presentations from ASH Minority Medical Student Award and Minority Resident Hematology Award program participants. The reception will also feature poster presentations by students participating in two Minority Research Supplement programs from the National Institutes of Health (NIH) as well as an announcement about the ASH-AMFDP Award, a partnership between ASH and the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation. Representatives from the NIH will be available to provide information about their training and research offerings.

Co-Chairs:

Belinda Rene Avalos, MD
Carolina HealthCare
Charlotte, NC

Georgette Dent, MD
Mayo Clinic
Rochester, MN

back to top

Social Media for the Hematologist: Today and in the Future

Sunday, December 2, 2018, 11:15 a.m. - 12:15 p.m.
San Diego Convention Center, Room 28D

Panelists will discuss the career benefits of participating in social media. They will provide an overview of the social media platforms that are most used by hematologists as well as the social media tools that hematologists may be using in the future.

Chair:

Aaron T. Gerds, MD,MS
Cleveland Clinic Taussig Cancer Institute
Cleveland, OH

Speakers:

Teresa Chan, MD
McMaster University
Hamilton, Canada
Background/Evolution of Social Media and Social Media as an Educational Tool

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, TX
How Has Social Media Augmented My Career/Practice as a Hematologist, and Why Does My Chair Care So Much About it?

Amber Yates, MD
Texas Children's Hospital
Houston, TX
How Social Media Has Helped My Career/Practice as a Hematologist

back to top

Special Education Session on ASH Clinical Practice Guidelines on Sickle Cell Disease

Sunday, December 2, 2018, 4:30 p.m. - 6:00 p.m.
San Diego Convention Center, Ballroom 20A

In response to long-standing member interest, ASH initiated an effort in 2014 to develop evidence-based clinical practice guidelines for hematology that meet the highest standards of development rigor and trustworthiness. In 2016, ASH began developing five guidelines on the management of acute and chronic complications of sickle cell disease (SCD). As a part of this effort, ASH is collaborating with the Mayo Clinic’s Evidence-Based Practice Center to support systematic evidence review.

More than 75 experts across five SCD guideline panels reviewed evidence and formulated more than 50 recommendations on SCD. In this session, the chairs of each of the five panels will present key recommendations from the upcoming chapters.

Chair:

Robert Liem, MD
Ann and Robert Lurie Children's Hospital of Chicago
Chicago, IL

Speakers:

Robert Liem, MD
Ann and Robert Lurie Children's Hospital of Chicago
Chicago, IL
Introduction to ASH Clinical Practice Guidelines on Sickle Cell Disease and Methodology

Ronisha Edwards, MSW
Department of Pediatrics, University of Illinois
Chicago, IL
Patient Representative

Stella T. Chou, MD
Children's Hospital of Philadelphia
Philadelphia, PA
Panel on Sickle Cell Disease-Related Transfusion Support

Sophie Lanzkron, MD
Johns Hopkins Medicine
Baltimore, MD
Panel on Sickle Cell Disease-Related Cardiopulmonary and Kidney Disease

Michael R. DeBaun, MD
Vanderbilt University Children's Hospital
Nashville, TN
Panel on Sickle Cell Disease-Related Cerebrovascular Disease

Amanda M. Brandow, DO, MS
Medical College of Wisconsin
Milwaukee, WI
Panel on Sickle Cell Disease-Related Pain

John F. Tisdale, MD
National Institutes of Health
Bethesda, MD
Panel on Stem Cell Transplantation for Sickle Cell Disease

back to top

Special Education Session on ASH Clinical Practice Guidelines on Venous Thromboembolism

Monday, December 3, 2018, 2:45 p.m. - 4:15 p.m.
San Diego Convention Center, Room 30D

In 2014, in response to long-standing member interest, ASH initiated an effort to develop evidence-based clinical practice guidelines for hematology that meet the highest standards of development rigor and trustworthiness. Development of these guidelines, including systematic evidence review, was supported by the McMaster University GRADE Center. Ten guideline panels, which included more than 100 thrombosis experts, reviewed evidence and formulated more than 200 recommendations on venous thromboembolism (VTE).

In this special session, four panelists will highlight particularly notable recommendations and will discuss important considerations for the practical application of the recommendations in practice.

Chair:

Adam Cuker, MD, MS
University of Pennsylvania
Philadelphia, PA

Speakers:

Susan Kahn, MD
Center for Clinical Epidemiology and Community Studies
Montreal, QC, Canada
Prophylaxis of Venous Thromboembolism (VTE) in Hospitalized Medical Patients

Wendy Lim, MD, MSc
McMaster University
Hamilton, ON, Canada
Diagnosis of Venous Thromboembolism (VTE)

Walter Ageno, MD
University of Insubria Varese
Varese, Italy
Treatment of Venous Thromboembolism (VTE)

Shannon M. Bates, MD, MSc
McMaster University
Hamilton, ON, Canada
Venous Thromboembolism (VTE) in the Context of Pregnancy

back to top

Special Session with the National Cancer Institute Director

Saturday, December 1, 2018, 5:45 p.m. - 6:15 p.m.
San Diego Convention Center, Hall AB

National Cancer Institute (NCI) Director Norman E. Sharpless, MD, will present his vision for the NCI along with the four key focus areas: big data, clinical trials, workforce development, and basic science. Dr. Sharpless will also discuss how the NCI vision and key focus areas may impact the greater hematology professional community.

Speaker:

Norman E. Sharpless, MD
National Cancer Institute
Bethesda, MD
Special Session with the National Cancer Institute Director

back to top

Special Symposium on ASH-Supported Researchers

Monday, December 3, 2018, 4:30 p.m. - 6:00 p.m.
San Diego Convention Center, Room 28D

ASH invites all interested meeting attendees to this event, which will showcase the research of ASH-funded scientists. Individual presentations will be made by recipients of the ASH Bridge Grant, ASH-AMFDP Award, ASH Scholar Award, ASH-EHA Translational Research Training in Hematology, ASH Clinical Research Training Institute, and ASH Research Training Award for Fellows.

Co-Chairs:

Charles G. Mullighan, MBBS, MD
St. Jude Children's Research Hospital
Memphis, TN

Anupama Narla, MD
Stanford University School of Medicine
Stanford, CA

Moderator:

Lindsay A.M. Rein, MD
Duke University School of Medicine
Durham, NC

Panelists:

Giada Bianchi, MD
Dana-Farber Cancer Insitute
Boston, MA

Francine E. Garrett-Bakelman, MD,PhD
University of Virginia School of Medicine
Charlottesville, VA

Kandace Gollomp, MD
Children's Hospital of Philadelphia
Philadelphia, PA

Pamela L. Wenzel, PhD
UT Health Science Center
Houston, TX

Lena E. Winestone, MD, MSHP
UCSF Benioff Children's Hospital
San Francisco, CA

Fenghuang Zhan, MD, PhD
University of Iowa Carver School of Medicine
Iowa City, IA

back to top

Special Symposium on Quality

Challenges Delivering and Measuring High-Quality Palliative Care for Patients With Hematologic Malignancies

Saturday, December 1, 2018, 2:00 p.m. - 3:30 p.m.
San Diego Convention Center, Room 11B

It is broadly recognized that providing high-quality symptom management, palliative care, and end-of-life (EOL) care is a critical dimension of cancer care. Previous research has suggested that patients with hematologic malignancies experience greater barriers to appropriate symptom management, timely palliative care, and higher intensity of care at the EOL, including higher rates of ICU admission, administration of chemotherapy in the weeks prior to death, and lower rates of hospice referral. On the other hand, there is controversy regarding how the quality of symptom management, palliative care, and EOL care should be measured for patients with blood cancers, as many of the existing metrics seem to have limited relevance. Moreover, systemic barriers may also exist that prevent patients with hematologic malignancies from accessing hospice care.

This session will review recent evidence regarding the quality of symptom management, palliative care, and EOL care that patients with blood cancers receive and how this care may differ from that received by other patients with other life-limiting diagnoses. Existing quality measures for EOL care will also be reviewed, in addition to controversies regarding how quality is measured in the context of pediatric and adult hematologic malignancies. Finally, speakers will discuss systemic and clinician-perceived barriers to timely hospice care for patients with blood cancers, along with new models of hospice tailored to their specific needs. 

For more on the topic of palliative care, please see the ASH Practice Partnership Lunch session, which will review barriers to incorporating high-quality palliative care into hematologic oncology as well as strategies for overcoming these barriers.

Co-Chairs:

Lisa K. Hicks, MD, MSc
St. Michael's Hospital
Toronto, ON, Canada

Gregory A. Abel, MD,MPH
Dana-Farber Cancer Institute
Boston, MA

Speakers:

Anthony O'Brien
Marymount University Hospital & Hospice
Dublin, Ireland
What Is Contemporary Palliative Care, and How and When Should It Be Integrated Into the Care of Patients With Serious Blood Disorders?

Kelly Marie Trevino, PhD
Weill Cornell Medicine
New York, NY
Measuring the Quality of Palliative Care in Hematologic Oncology: Are Current Measures Meaningful and/or Sufficient for Patients and/or Blood Cancers? What Types of Measures Do We Need?

David Hui, MD
The University of Texas MD Anderson Cancer Center
Houston, TX
Are Patients With Blood Cancers Receiving Quality Palliative and End-of-Life Care?

back to top

Systems-Based Hematology Education and Networking Session

Engaging Leadership: How to Garner Support and Resources for Systems-Based Hematology in Academic and Community Settings

Sunday, December 2, 2018, 4:30 p.m. - 6:30 p.m.
San Diego Convention Center, Room 7B

A key issue for nascent systems-based hematologists is convincing hospital administrators that the time and expense related to either full- or part-time systems-based hematology activities provides value to the institution. This can be in the form of increased quality of care, reduced operating costs, lowered utilization of limited resources, or other enhancements to clinical efficiency. Whether the goal is hiring a full-time systems-based hematologist or simply carving out time and providing resources for a clinician to perform similar work, administrators and other gatekeepers require both a rationale and evidence for why it is worth the effort.

In this session, practicing systems-based hematologists from both academic and community settings will be joined by their administrators to discuss the business case for systems-based hematology and strategies for securing resources. The latter half of the session will be devoted to networking with the speakers and other systems-based hematologists over drinks and hors d'oeuvres.

Chair:

Colleen Morton, MD
Vanderbilt University Medical Center
Nashville, TN

Speakers:

David A. Garcia, MD
University of Washington
Seattle, WA
Strategies for Securing Support in Academic Medical Systems

Thomas O. Staiger, MD
University of Washington
Seattle, WA
Strategies for Securing Support in Academic Medical Systems

Janice W. Lawson, MD
Tallahassee Memorial HealthCare
Tallahassee, FL
Strategies for Securing Support in Community Medical Systems

Dean D. Watson, MD
Tallahassee Memorial HealthCare
Tallahassee, FL
Strategies for Securing Support in Community Medical Systems

back to top

Training Program Directors' Workshop

Friday, November 30, 2018, 11:00 a.m. - 2:00 p.m.
Petco Park, The Auditorium

This workshop offers an interactive forum for fellowship directors to learn about issues facing them and engage in topic-based conversations with educators, regulators, and other training program directors. The workshop is designed to facilitate discussion and the sharing of best practices in critical training areas.

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

ASH designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Chair:

Hetty E. Carraway, MD, MBA
Cleveland Clinic
Cleveland, OH

Speakers:

Laura Edgar, EdD, CAE
ACGME
Chicago, IL
Program Director Role in Clinical Competency Committee Evaluation

Elaine A. Muchmore, MD
University of California – San Diego
San Diego, CA
Program Director Role in Clinical Competency Committee Evaluation

Michael Linenberger, MD
Seattle Cancer Care Alliance
Seattle, WA
Resiliency in Fellowship

Annie Im, MD
University of Pittsburgh Cancer Institute
Pittsburgh, PA
Top Ten Pearls and Pitfalls for Fellowship Program Directors

Ann S. LaCasce, MD, MSc
Dana-Farber Cancer Institute
Boston, MA
Top Ten Pearls and Pitfalls for Fellowship Program Directors

Alice Ma, MD
University of North Carolina at Chapel Hill
Chapel Hill, NC
Top Ten Pearls and Pitfalls for Fellowship Program Directors

back to top